pspawareness - Twitter Search / Twitter
Biogen's Tau Antibody Fails In PSP, But Alzheimer's Studies Continue :: Scrip
Biogen on Twitter: "#DYK…Progressive supranuclear palsy (#PSP) is a neurodegenerative disorder that affects the brain cells controlling balance, walking, coordination, eye movement, speech, swallowing and thinking. #AANAM https://t.co/uYb551MjJi" / Twitter
Biogen on Twitter: "Our #MultipleSclerosis (#MS) and progressive supranuclear palsy (#PSP) research will be highlighted in the poster sessions today at #AANAM https://t.co/4HA0yQOW8X" / Twitter
Biogen | Contract Pharma
Biogen Acquires Alzheimer's and Parkinson's Asset from Pfizer in $710 Million Deal | BioSpace
Cover Layout Presentation name
Biogen looks to M&A to overcome competition to its MS franchise | Fierce Pharma
Biogen deals the tau pipeline another blow | Evaluate
PSP — Coleen Heaver
Biogen 2019 Outlook (NASDAQ:BIIB) | Seeking Alpha
Research | Pipeline
Biogen - Pioneers In Neuroscience
Overview of Tau immunotherapies in clinical trial. Indicated are... | Download Scientific Diagram
Biogen on Twitter: "We'll be showcasing our work in neuroscience including the areas of multiple sclerosis (#MS), spinal muscular atrophy (#SMA), Alzheimer's Disease (#AD) and progressive supranuclear palsy (#PSP) with poster and
Twitter \ Biogen on Twitter: "#DYK progressive supranuclear palsy (#PSP) wasn't discovered until 1963 due to its resemblance to Parkinson's disease? #PSPAwarenessMonth https://t.co/59rxSezyHe"
Gosuranemab: another Alzheimer's candidate to bite the dust
Biogen's Tau Antibody for Progressive Supranuclear Palsy Fails Trial | BioSpace
Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug - Boston Business Journal
Biogen abandons tau antibody for Alzheimer's after phase 2 miss -
Bristol-Myers offloads anti-tau, DMD assets to Biogen, Roche for $470M upfront, $615M in milestones | Fierce Biotech
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb - Pharmaceutical Processing World
Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 United States PROTOCOL NUMBER: 251PP301 / NCT03068468 Biogen Idec Research
